# Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer

> **NCT00912444** · PHASE3 · TERMINATED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 102 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
- **DRUG:** Docetaxel, cyclophosphamide

## Key facts

- **NCT ID:** NCT00912444
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2012-05
- **Final completion:** 2015-10
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912444, "Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00912444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*